1-methyl-1-(4-fluorophenyl)ethanethiol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-methyl-1-(4-fluorophenyl)ethanethiol
• 英文别名: 2-(4-Fluorophenyl)propane-2-thiol
• 化学式: C₉H₁₁FS
• 分子量: 170.251
• InChiKey: FVSXKMNVSHRKOR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  劳森试剂 、 2-(4-氟苯基)-2-丙醇 以 甲苯 为溶剂， 以214 mg (28%)的产率得到1-methyl-1-(4-fluorophenyl)ethanethiol
  参考文献：
  名称：

  Heterosubstituted pyridine derivatives as PDE 4 inhibitors

  摘要：

  该发明涵盖了一种新型化合物，其化学式为I，可用于治疗包括哮喘在内的疾病，通过通过抑制磷酸二酯酶IV（PDE 4）提高环状腺苷-3′,5′-单磷酸酯（cAMP）的水平。该发明还涵盖了药物组合物和治疗方法。

  公开号：

  US06316472B1

文献信息

• HETEROSUBSTITUTED PYRIDINE DERIVATIVES AS $i(PDE 4) INHIBITORS
  申请人：Merck Frosst Canada & Co.

  公开号：EP1189888A1

  公开（公告）日：2002-03-27
• INHIBITORS OF KRAS G12C
  申请人：Araxes Pharma LLC

  公开号：US20210188869A1

  公开（公告）日：2021-06-24

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R 1 , R 2a , R 3a , R 3b , R 4a , R 4b , G 1 , G 2 , L 1 , L 2 , m 1 , m 2 , A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
• US6316472B1
  申请人：——

  公开号：US6316472B1

  公开（公告）日：2001-11-13
• [EN] HETEROSUBSTITUTED PYRIDINE DERIVATIVES AS PDE 4 INHIBITORS<br/>[FR] DERIVES DE PYRIDINE HETEROSUBSTITUES, EN TANT QU'INHIBITEURS DE PDE 4
  申请人：MERCK FROSST CANADA INC

  公开号：WO2000069824A1

  公开（公告）日：2000-11-23

  The invention encompasses the novel compound of Formula (I) useful in the treatment of diseases, including asthma, by raising the level of cyclic adenosine-3',5'-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE 4). The invention also encompasses pharmaceutical compositions and methods for treatment.
• Heterosubstituted pyridine derivatives as PDE 4 inhibitors
  申请人：Merck Frosst Canada & Co.

  公开号：US06316472B1

  公开（公告）日：2001-11-13

  The invention encompasses the novel compound of Formula I useful in the treatment of diseases, including asthma, by raising the level of cyclic adenosine-3′,5′-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE 4). The invention also encompasses pharmaceutical compositions and methods for treatment.

  该发明涵盖了一种新型化合物，其化学式为I，可用于治疗包括哮喘在内的疾病，通过通过抑制磷酸二酯酶IV（PDE 4）提高环状腺苷-3′,5′-单磷酸酯（cAMP）的水平。该发明还涵盖了药物组合物和治疗方法。